Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) will pursue licensing and acquisitions to expand its speciality business, the company's senior executive said. "M&A - we have always tried to be very judicious; looked at ways by which we can use licensing or acquisitions as a way to fill the gaps in our portfolio and achieve our strategic goal," said Abhay Gandhi, CEO-North America Business at Sun Pharma."Of course, having a cash chest of close to $2.4 billion inclusive of Taro enables us to pursue mid- to large-size transactions as well," Gandhi said. He added in the past few years Sun Pharma has been making conscious efforts to develop a pipeline of products in-house and "going ahead, it will be a combination of both (M&A and inhouse development)".
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,497 INR | +0.20% |
|
-1.52% | +18.92% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.92% | 42.97B | |
+24.56% | 22.16B | |
+20.32% | 14.56B | |
+54.96% | 13.03B | |
-0.05% | 6.79B | |
-11.35% | 6.46B | |
+17.73% | 5.87B | |
-8.87% | 5.73B | |
+6.11% | 4.61B | |
+23.18% | 4.48B |
- Stock Market
- Equities
- SUNPHARMA Stock
- News Sun Pharmaceutical Industries Ltd.
- Sun Pharma to Pursue M&A